Medical devices, healthcare technology and the business of care
PMA approval · P130030

REBEL PLATINUM CHROMIUM CORONARY STENT SYSTEM MONORAIL AND OVER THE WIRE

Boston Scientific Corp · Decision date Mar 10, 2026

FDA DECISIONP130030

What did the FDA approve?

FDA records P130030 as an original PMA application. The recorded decision is approval, dated Mar 10, 2026.

FDA approval order statement

APPROVAL FOR THE REBEL PLATINUM CHROMIUM CORONARY STENT SYSTEM (MONORAIL AND OVER-THE-WIRE). THIS DEVICE IS INDICATED FOR IMPROVING CORONARY LUMINAL DIAMETER IN PATIENTS WITH DE NOVO LESIONS <= 28 MM IN LENGTH IN NATIVE CORONARY ARTERIES WITH A REFERENCE VESSEL DIAMETER (RVD) OF >= 2.25 TO >= 4.50 MM.
Regulatory pathway
Original PMA
Clinical specialty
Cardiovascular
Decision date
Mar 10, 2026

FDA source record

Regulatory record facts

Identifier
P130030
Regulatory pathway
Premarket approval application
Product code
MAF
Decision code
APPR
Decision date
Mar 10, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: STENT, CORONARY.

Product code
MAF
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P130030 received

    Application receipt date recorded by FDA.

  2. P130030 · FDA decision

    APPR

Timeline entries are records held by MedtechLedger for P130030. View FDA’s full supplement list.

Related devices and submissions

Explore the linked device profile

Other records with product code MAF

Product / regulatory recordCompanyPathwayDecision dateSource
Biotronik AGPMA supplementJun 5, 2026FDA
Biotronik AGPMA supplementApr 15, 2026FDA
Biotronik AGPMA supplementApr 1, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Boston Scientific Corp

Headquarters
Not reported
FDA applicant address
One Scimed Pl., Maple Grove, MN, 55311

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records